Literature DB >> 134291

Spastic paresis after 6-aminonicotinamide: metabolic disorders in the spinal cord and electromyographically recorded changes in the hind limbs of rats.

H Herken, G Meyer-Estorf, K Halbhübner, D Loos.   

Abstract

In rats the application of 10 mg/kg 6-amino-nicotinamide (6-AN) leads to an accumulation of 6-phosphogluconate, by inhibition of 6-phosphogluconate dehydrogenase in the pentose phosphate pathway, in the cells of the spinal cord. The accumulation reaches its maximum after 18-24 h. It seems that there exists a relationship between the accumulation of 6-phosphogluconate and the lesion of the neuroglia, which is found in electron microscopic studies. Symptoms of a spastic paresis only develop later when the spinal interneurones are destroyed as a consequence of the lesion of the neuroglia. The accumulation of 6-phosphogluconate almost exceeds the 400 fold of the norm. No considerable differences are found between the effects of a dose of 35 mg 6-AN/kg and one of 10 mg 6-AN/kg. Free gluconate is identified enzymically in the cells of the spinal cords of the rats treated with 6-AN. The compound is very probably formed by dephosphorylation and diffuses into the blood. 6-Phosphogluconate is an inhibitor of the phosphoglucose isomerase. Its accumulation shifts the equilibrium towards glucose 6-phosphate. The lactate concentration decreases as compared with the untreated controls. Muscular action potentials are recorded extracellularly with a concentric needle electrode from the musculus gastrocnemius of rats treated with 6-AN. First activations of the electromyograms are found 48 h after the application of 10 mg 6-AN/kg. The electrical activities increase during the time in which a progressive destruction of the interneurones occurs. The electromyogram displays a permanent state of excitation with high amplitudes and an increased frequency. The continuity and intensity of the increased activity recorded by the electromyograph is the most important pathological finding. p-Chlorophenyl-GABA and, still more so, chlorpromazine cause temporary reduction of the excitation processes and an electromyogram nearly at rest. Under the same conditions, haloperidol is only slightly effective. The symptoms developed by the chemical destruction of the interneurones of the spinal cord, with rigidity and spasticity of the hind limbs, are suitable for testing antispastic drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 134291     DOI: 10.1007/bf00507347

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

1.  Renal gluconate excretion after 6-aminonicotinamide.

Authors:  H Herken; K Keller; H Kolbe; K Lange
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  [DAMAGE TO THE CENTRAL NERVOUS SYSTEM BY ANTIMETABOLITES OF NICOTINAMIDE. A CONTRIBUTION TO MOLECULAR PATHOLOGY OF PYRIDINE NUCLEOTIDES].

Authors:  H COPER; H HERKEN
Journal:  Dtsch Med Wochenschr       Date:  1963-10-18       Impact factor: 0.628

3.  EFFECT OF ISCHEMIA ON KNOWN SUBSTRATES AND COFACTORS OF THE GLYCOLYTIC PATHWAY IN BRAIN.

Authors:  O H LOWRY; J V PASSONNEAU; F X HASSELBERGER; D W SCHULZ
Journal:  J Biol Chem       Date:  1964-01       Impact factor: 5.157

4.  Pathological changes in the central nervous system produced by 6-aminonicotinamide.

Authors:  A WOLF; D COWEN
Journal:  Bull N Y Acad Med       Date:  1959-12

5.  6-Aminonicotinamide--a Potent Nicotinamide Antagonist.

Authors:  W J Johnson; J D McColl
Journal:  Science       Date:  1955-10-28       Impact factor: 47.728

6.  [The effect of insulin on the transport of potassium in skeletal muscles].

Authors:  R Sitt; W Losert; G Schlutz; H Kaess; G Senft
Journal:  Naunyn Schmiedebergs Arch Pharmakol Exp Pathol       Date:  1966

7.  [The effect of 6-aminonicotinamide on the distribution of sodium and potassium ions between the extracellular and intracellular space in the liver and skeletal muscles].

Authors:  H Herken; G Senft; B Zemisch
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1966

8.  Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action.

Authors:  J J Schildkraut; S M Schanberg; G R Breese; I J Kopin
Journal:  Am J Psychiatry       Date:  1967-11       Impact factor: 18.112

9.  Distribution of 3 H-labelled 6-aminonicotinamide and accumulation of 6-phosphogluconate in the spinal cord.

Authors:  G Meyer-Estorf; P E Schulze; H Herken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

10.  Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor.

Authors:  B K Yeh; J L McNay; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1969-08       Impact factor: 4.030

View more
  3 in total

Review 1.  [Nerve cell clonal lines in culture--models for studying the molecular basis of neuropharmacological actions].

Authors:  H Herken
Journal:  Klin Wochenschr       Date:  1983-01-03

2.  Lisuride, a potent drug in the treatment of muscular rigisity in rats.

Authors:  D Loos; K Halbhübner; H Herken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

3.  Impaired dopamine function and muscular rigidity induced by 6-aminonicotinamide in rats.

Authors:  W Kehr; K Halbhübner; D Loos; H Herken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.